GANX
Gain Therapeutics Inc

2,489
Mkt Cap
$100.39M
Volume
97,263.00
52W High
$4.34
52W Low
$1.41
PE Ratio
-4.08
GANX Fundamentals
Price
$2.59
Prev Close
$2.61
Open
$2.56
50D MA
$2.33
Beta
1.17
Avg. Volume
1.09M
EPS (Annual)
-$0.892
P/B
15.89
Rev/Employee
$0.00
$39.69
Loading...
Loading...
News
all
press releases
Gain Therapeutics, Inc. (NASDAQ:GANX) Receives Consensus Recommendation of "Moderate Buy" from Brokerages
Gain Therapeutics, Inc. (NASDAQ:GANX - Get Free Report) has been assigned a consensus rating of "Moderate Buy" from the seven analysts that are presently covering the firm, Marketbeat reports. One...
MarketBeat·9d ago
News Placeholder
More News
News Placeholder
Gain Therapeutics, Inc. (NASDAQ:GANX) Short Interest Up 19.9% in January
Gain Therapeutics, Inc. (NASDAQ:GANX - Get Free Report) was the recipient of a significant increase in short interest during the month of January. As of January 30th, there was short interest...
MarketBeat·13d ago
News Placeholder
Gain Therapeutics, Inc. (NASDAQ:GANX) Receives Consensus Recommendation of "Moderate Buy" from Analysts
Shares of Gain Therapeutics, Inc. (NASDAQ:GANX - Get Free Report) have been assigned a consensus rating of "Moderate Buy" from the seven brokerages that are currently covering the stock...
MarketBeat·1mo ago
News Placeholder
Short Interest in Gain Therapeutics, Inc. (NASDAQ:GANX) Rises By 28.6%
Gain Therapeutics, Inc. (NASDAQ:GANX - Get Free Report) was the target of a significant growth in short interest during the month of December. As of December 31st, there was short interest totaling...
MarketBeat·1mo ago
News Placeholder
Gain Therapeutics Shares Early Phase 1b Data: GT-02287 Shows UPDRS Gains, Key PD Biomarker Drop
Gain Therapeutics (NASDAQ:GANX) highlighted early clinical and biomarker findings from the first 90 days of its ongoing Phase 1b open-label study evaluating GT-02287 in people with Parkinson's...
MarketBeat·2mo ago
News Placeholder
Gain Therapeutics, Inc. (NASDAQ:GANX) Receives Consensus Rating of "Moderate Buy" from Brokerages
Gain Therapeutics, Inc. (NASDAQ:GANX - Get Free Report) has been given a consensus rating of "Moderate Buy" by the seven brokerages that are currently covering the firm, Marketbeat reports. One...
MarketBeat·2mo ago
News Placeholder
Gain Therapeutics, Inc. (NASDAQ:GANX) Short Interest Update
Gain Therapeutics, Inc. (NASDAQ:GANX - Get Free Report) saw a significant growth in short interest in December. As of December 15th, there was short interest totaling 2,073,310 shares, a growth of...
MarketBeat·2mo ago
News Placeholder
Gain Therapeutics (GANX) Upgraded to Buy: Here's Why
Gain Therapeutics (GANX) has been upgraded to a Zacks Rank #2 (Buy), reflecting growing optimism about the company's earnings prospects. This might drive the stock higher in the near term.
Zacks·2mo ago
News Placeholder
Gain Therapeutics (NASDAQ:GANX) Receives Buy Rating from HC Wainwright
HC Wainwright reiterated a "buy" rating and set a $8.00 price target on shares of Gain Therapeutics in a research report on Friday...
MarketBeat·2mo ago
News Placeholder
Is Enhabit, Inc. (EHAB) Stock Outpacing Its Medical Peers This Year?
Here is how Enhabit (EHAB) and Gain Therapeutics, Inc. (GANX) have performed compared to their sector so far this year.
Zacks·2mo ago
<
1
2
...
>

Latest GANX News

View
Top Discussions

Advertisement|Remove ads.

Advertisement|Remove ads.